Cargando…
Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
Autores principales: | Dass, Ashwitha S., Immaculate, Gloria, Bhattacharyya, Arpandev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446678/ https://www.ncbi.nlm.nih.gov/pubmed/31016172 http://dx.doi.org/10.4103/ijem.IJEM_614_18 |
Ejemplares similares
-
Fournier’s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications
por: Kasbawala, Kinjal, et al.
Publicado: (2020) -
A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022) -
Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy
por: Chowdhury, Tutul, et al.
Publicado: (2022) -
Fournier’s Gangrene under Sodium–Glucose Cotransporter-2 Inhibitors Therapy in Gynecological Patients
por: Serrano Olave, Adriana, et al.
Publicado: (2022) -
D1 MTE2 Case 4: A case of men - 1
por: Dass, Ashwitha Shruti, et al.
Publicado: (2022)